Drug intelligence / Profile preview

Neiyifang

Development stage: Unknown
Lead developer: Foshan Fosun Chancheng Hospital
Administration: Oral

Overview

Neiyifang is a Traditional Chinese Medicine (TCM) formulation developed by Foshan Fosun Chancheng Hospital for the treatment of endometriosis and associated dysmenorrhea. It is administered as either a granule or a decoction. The formula is designed to alleviate pain and address the underlying pathology of endometriosis, likely through mechanisms involving blood stasis removal and inflammation modulation, which are common targets in TCM for this condition. Clinical research is currently focused on establishing its dose-effect relationship, safety profile, and specific biological mechanisms in patients with endometriosis-related dysmenorrhea.

Brand names: 内异方
Other names: Neiyifang granuleNeiyifang decoction

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on Neiyifang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neiyifang.

Explore the full profile